Gautam, Nagsen
McMillan, JoEllyn M.
Kumar, Devendra
Bade, Aditya N.
Pan, Qiaoyu
Kulkarni, Tanmay A.
Li, Wenkuan
Sillman, Brady http://orcid.org/0000-0002-7123-3034
Smith, Nathan A.
Shetty, Bhagya L. Dyavar
Szlachetka, Adam
Edagwa, Benson J. http://orcid.org/0000-0003-1484-9331
Gendelman, Howard E. http://orcid.org/0000-0002-7831-0370
Alnouti, Yazen
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (5 P01 DA028555-10)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (5 R01 AI45542-01)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (5 R01 MH121402-02, 5 P30 MH062261-19)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Article History
Received: 22 January 2021
Accepted: 7 May 2021
First Online: 8 June 2021
Competing interests
: B.E. and H.E.G. are cofounders of Exavir Therapeutics, Inc. and are inventors on a patent that cover year-long integrase inhibitor prodrug formulations (PCT/US2019/057406, WO2020-086555). All other authors declare no competing interests.